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????2011? 4??? 2017? 3????????









?????? TE????????? A?? 4.3%?B
?? 7.9%???????????????????
A?? 6.5%?B?? 15.8%????????????




























?27.5%??T4 : 38/51?74.5%??nonT4 : 13/51?25.5%??















































































































D??? 1.5 cm?????? Bp?????????




ANA?????????1??? follow up CT??
S8? 3cm?????????PET-CT??????
































? 7????? 3????? 3?????? 3???

































?? 2????? TE?????? 2???????
????????????? 5?????SBI???























































































??? 2018? 10? 31??? 3,237???????
?????????372? ?11.5%??GC164? ?5.1%??
BRCA1/2???? 15?????????? 3???














































































































































































??????T4bN2a?level I 27/27, level II 8/8?M0 
StageIIIB ??????????NA2 MC3 NG3?Ki67 
40-60%?ER 90%?PR 3-5%?HER2 ????????













































































?paclitaxel : PTX?+???????bevacizumab : Bev?
?PTX 80 mg/m2  3??? 1????Bev 10 mg/kg, day 






































































??? DMG? C-3?????? DBT? C-3???
??????? 24??4.6%?????18?? DMG
? FAD????????????? distortion????





???????? spiculated mass? 1???????
































































??????????? 29? 4????? 30? 3?






??? 4??50%????? 3??36%????? 1?
?14%?????? 0.7?? 4??50%??0.7?? 4?
?50%????????????? 4??50%????










































































































54?? 83?? 2??? cStage4??Invasive ductal 
carcinoma No Special Type ????1 ?? ER ???
PgR???MIB-1 index : 10%?1?? ER???PgR
???MIB-1 index : 33%????????????
???? 1?? Letrozole?1?? Paclitaxel +Bevasi-
zumab? Eribulin???????1?????1 ??




























??????? X+1? Z????? 5??????
???????????????? C??????
????????????????MMG?? C4?





?????? T2N1M0 StageIIB ACC NA1 MC2 NG2 
















???? 68.3??????? 2 : 1?? :??????




























PgR????HER2????ki-67 : 41%?N?+?: 1/18?






















CD ??? 8 mm????????? 3??????
CT?????? 6 mm ?????????????
??????????MRI???????????
????Core needle biopsy?CNB? ?????Inva-
sive cribriform carcimoma?????????? ICC??
ER??PgR??HER2??????????????
????????????????????????







pure type?classical type?mixed type? 3?????
????????????????????????

















???????? ACDE????? 77 mm×?? 75 





???? 1???????? 90×60 mm?????
????????????????????????
????????????????????????












































????? 30 Gy????????HER?? 12??
114 ? 16????????????
???????? PD??????????????























?????X? 10???? B??? 5 cm????
????????????????? 2/3?????
??CNB? TNBC?Ki-67 : 80%?CT????????
?????????? AC?? 3??????? PD?
???? 1?????????????wPTX 3??
?? PD?X+1? 3?? Bt???? B??????
????????? IDC ????TNBC?Ki-67 : 
84%???????????????????????
???? X+1? 6??? level I?III???????
????? Bt? Ax?III?????????????
??????????????????????


































































































































































































????????? Invasive lobular carcinoma?ER 8?
PgR  7?HER2 +2 FISH 2.0 ?????????CT?
????????????T4N2M1?Stage IV?????
FEC 5?????????????????????
??NVB+Herceptin, Capecitabine+Herceptin, Kadcyla, 
NVB+Herceptin+Perjeta,  DOC+Herceptin+Perjeta, 
Herceptin+Perjeta+Eribulin, Herceptine+nabPTX, 
Herceptin+Perjeta+nabPTX???????????





MTX+AC+PSL ? ? ? ? ? ? ? ? ? ? ? ??
Capecitabine+Lapatinib?????????????














































































































??? 1???? 3??2???? 3??3????
?? 13????????? 125 mg???????
???? 1??????1????????? 8??
?????????? Grade 3???????? 8??
Grade 4???????? 1?????????? 1























?? 11??????? line??? 1???????
??? 0??2?????????? 2??3???
? 9???????????????????????
HER2??????????? Visceral? 9??Non 




???SD? 2??PD ? 4???? 4??????
?????????????Paloma-2??? Paloma-3
??? Objective response?OR?????? 42.1%?
27.3%??????? OR????????????


























???? 62??44-83???? /?? =20/3???? /
???? ER??????PR?? 4??????
Fulvestrant/Letrozol/LH- RH agonist=18/5/4 ????
line? 1st/2nd/3rd/4-5th/6-8th=3/4/3/4/8 ?? 4th??
???????????? 4.1???? 5??????
6.2????3-12????????????? PR/SD/
PD=4/17/2???PR???? line? 2nd?3rd ? 1?
?????????7th 2?????????????





























































tor ?ER? ? ??progesteron receptor ?PgR? ? ??

















































HER?1+?? HER? 3+? 1+?FISH??????
???????????????????????


















?????? : 44??????? : ???????
?? : ??????? : ????????????
???????????????????? : 2015
? 6????????? C???????????
??????????? : ? C?? 35 mm????
????????????? AC?? 10 mm???
????????? : ??????????? IDC
?solid-tubular??ER TS3?PgR TS0?HER2 0?Ki67 
60%?T2 N1 M0 cStageIIB?????????? IDC
?scirrhous??ER TS0?PgR TS0?HER2 0?Ki67 30%?




?? PR?????2016? 5???????? Bt?
Ax?II?????? : Grade1a???????? Bt?
SN? Ax?II????? : Grade3??????????

































































































































































































































????????????????? 29 ? 4????






























































































































?? 1???? 1??????????? 29? 1?




















































???? Performance status?PS???PS1? 1??








































































































































2006? 1??? 2018? 12???????????
?????? 8????? 1 cm??????????
????????????????????????






































































































































































????? P??????????? 4 ??Luminal-
HER2? cStage3A??????dose dense EC?Epiru-
bicine + Cyclophosphamide???? Trastuzumab?H?

































survival ?DFS??overall survival ?OS????????
??????????????????? pCR?
ypT0/ypTis and ypN0 ?????????1??????
???? : ???? 50.8±10.7??????? cStage 
IIb/IIIa/IIIb/IIIc ?31/13/ 15/ 7???ER?? 31/66?47%??
HER2?? 9/66?14%? ????????????
TN?28/66?42%????????? 34/66?52%????
?2??? pCR? 21/66??31.8%??non-pCR ? 45/66
??68.2%???3?pCR?non-pCR ? 5 ? DFS?95.2% 
vs 66.7%? Log- rank p= 0.01?5 ? OS?95.2% vs 











































































??2014 ? 2 ??2015 ? 4 ??2016 ? 4 ??2017
? 13??2018? 17????????????? 42 
???? OncotypeDx??????????????
????? 36?69????? 50?????? 23? /
? ? ? 19 ??Stage1 : 25 ? /2A : 16 ? /3B : 1 ??
???? 6 mm?38 mm???? 17.5 mm?,??? Bt
?SSM/NSM???9 ? /Bp33??SN?? 39? /??
?? 3????????? n0 : 33??n+ : 9??
OncotypeDx ??? RS ? 0?38 ????????
17?: 19????????18?30?: 18???????31
??: 5????????????????????
?????????? 12????????????
?? 5??????? 7?????????????
? TC?????????????????????
OncotypeDx?????????????????
